Wenjin Yin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wenjin Yin has a total of 184 co-authors. Here are the top co-authors by number of shared publications:
- Jinsong Lu
Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
69 shared publications Yanping Lin
Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
35 shared publicationsLiheng Zhou
Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University
33 shared publicationsYaohui Wang
Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
27 shared publicationsShuguang Xu
Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
26 shared publicationsYueyao Du
25 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
Disitamab vedotin triggers ferroptosis to activate CD8+ T-cell antitumor immunity in HER2-expressing breast cancer
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is highly aggressive and is associated with poor prognosis after metastasis or recurrence. The development of anti-HER2 antibody–drug conjugates (ADCs) has markedly improved outcomes. Disitamab vedotin (RC48) is a novel anti-HER2 ADC that exhibits antitumor activity against both HER2-positive and HER2-low breast cancers, although its molecular mechanism of action remains incompletely understood. Here, we show that RC48 triggers the accumulation of lipid reactive oxygen species (ROS), thereby inducing ferroptosis and the subsequent release of damage-associated molecular patterns (DAMPs) that initiate immunogenic cell death (ICD). DAMP emission promotes dendritic cell maturation and increases CD8 + T-cell infiltration and cytotoxicity within the tumor microenvironment. In vivo mouse models confirm the efficacy and safety of RC48 both as a monotherapy and as part of a combination therapy with anti-programmed cell death ligand 1 (PD-L1). Collectively, our findings delineate a ferroptosis–ICD–immune axis underlying the antitumor activity of RC48 and support its clinical development as a monotherapy or in combination with immune checkpoint inhibitors for HER2-expressing breast cancer.
- 29 September 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
Open AccessDisitamab vedotin triggers ferroptosis to activate CD8+ T-cell antitumor immunity in HER2-expressing breast cancer
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is highly aggressive and is associated with poor prognosis after metastasis or recurrence. The development of anti-HER2 antibody–drug conjugates (ADCs) has markedly improved outcomes. Disitamab vedotin (RC48) is a novel anti-HER2 ADC that exhibits antitumor activity against both HER2-positive and HER2-low breast cancers, although its molecular mechanism of action remains incompletely understood. Here, we show that RC48 triggers the accumulation of lipid reactive oxygen species (ROS), thereby inducing ferroptosis and the subsequent release of damage-associated molecular patterns (DAMPs) that initiate immunogenic cell death (ICD). DAMP emission promotes dendritic cell maturation and increases CD8 + T-cell infiltration and cytotoxicity within the tumor microenvironment. In vivo mouse models confirm the efficacy and safety of RC48 both as a monotherapy and as part of a combination therapy with anti-programmed cell death ligand 1 (PD-L1). Collectively, our findings delineate a ferroptosis–ICD–immune axis underlying the antitumor activity of RC48 and support its clinical development as a monotherapy or in combination with immune checkpoint inhibitors for HER2-expressing breast cancer.
- Open Access
- 17 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4493
Construction of a Lysine Lactylation- and DNA Damage Repair-Related Gene Signature to Predict the Prognosis and Drug Sensitivity of Breast Cancer Patients
Breast cancer is prevalent and deadly, affecting women worldwide. Increasing research suggests that lysine lactylation (KLA) and DNA damage repair (DDR) play critical roles in tumor progression and that KLA and DDR are interconnected, as KLA can modulate DDR protein function, thereby influencing genome stability and drug response, while DDR signaling can reciprocally reshape lactate metabolism and KLA activity. In this study, we developed a novel prognostic gene signature (KLA and DDR index, KLDRI) based on KLA- and DDR-related genes. Model genes (PGK1, MORF4L2, RAD54B, RPA3, CCND2) were generated via LASSO-Cox regression. Patients were stratified into high- and low-risk groups according to KLDRI, the robust prognostic value of which was demonstrated via survival and validation analyses in the TCGA cohort and the METABRIC and GSE96058 cohorts, respectively. Tumor microenvironment analysis indicated an immunologically suppressed phenotype in high-risk patients, whereas low-risk patients exhibited an immune-inflamed microenvironment. Drug sensitivity analysis indicated reduced sensitivity to multiple chemotherapy and targeted therapy drugs in the high-risk group. Single-cell transcriptomic analysis revealed differential gene expression patterns between risk groups. A prognostic nomogram based on KLDRI was developed to predict overall survival. Furthermore, functional experiments demonstrated that RPA3 knockdown suppressed cancer cell proliferation and migration, sensitized cells to cisplatin treatment, and reduced global lactylation, which may serve as a novel biomarker and potential therapeutic target. These findings enhance our understanding of the interplay between KLA, DDR, and breast cancer progression, facilitating the development of personalized therapeutic strategies.
- 17 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4493
Open AccessConstruction of a Lysine Lactylation- and DNA Damage Repair-Related Gene Signature to Predict the Prognosis and Drug Sensitivity of Breast Cancer Patients
Breast cancer is prevalent and deadly, affecting women worldwide. Increasing research suggests that lysine lactylation (KLA) and DNA damage repair (DDR) play critical roles in tumor progression and that KLA and DDR are interconnected, as KLA can modulate DDR protein function, thereby influencing genome stability and drug response, while DDR signaling can reciprocally reshape lactate metabolism and KLA activity. In this study, we developed a novel prognostic gene signature (KLA and DDR index, KLDRI) based on KLA- and DDR-related genes. Model genes (PGK1, MORF4L2, RAD54B, RPA3, CCND2) were generated via LASSO-Cox regression. Patients were stratified into high- and low-risk groups according to KLDRI, the robust prognostic value of which was demonstrated via survival and validation analyses in the TCGA cohort and the METABRIC and GSE96058 cohorts, respectively. Tumor microenvironment analysis indicated an immunologically suppressed phenotype in high-risk patients, whereas low-risk patients exhibited an immune-inflamed microenvironment. Drug sensitivity analysis indicated reduced sensitivity to multiple chemotherapy and targeted therapy drugs in the high-risk group. Single-cell transcriptomic analysis revealed differential gene expression patterns between risk groups. A prognostic nomogram based on KLDRI was developed to predict overall survival. Furthermore, functional experiments demonstrated that RPA3 knockdown suppressed cancer cell proliferation and migration, sensitized cells to cisplatin treatment, and reduced global lactylation, which may serve as a novel biomarker and potential therapeutic target. These findings enhance our understanding of the interplay between KLA, DDR, and breast cancer progression, facilitating the development of personalized therapeutic strategies.
- Open Access
- 1 May 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (3) , 101924
Leveraging a chromosomal instability-based signature to predict the prognosis and immune landscape of breast cancer
Chromosomal instability (CIN) significantly impacts the tumor progression and tumor immune microenvironment (TIME). However, few researchers have focused on CIN variables in predicting prognosis and the immune landscape of breast cancer. Through unsupervised consensus clustering, the TCGA-BRCA cohort was categorized into two clusters based on the CIN25 gene signature. After identifying the two clusters’ differentially expressed genes, we sequentially performed univariate Cox, LASSO, and multivariate Cox regression analyses to construct a 13-gene signature, termed “CIN score”. Then, the breast cancer patients were divided into low- and high-CIN score groups. The differences in survival outcome, clinicopathological parameters, TIME, and drug sensitivity between the two groups were further investigated. The high-CIN score group had unfavorable clinicopathological features and overall survival. TIME analysis indicated that the low-CIN score group had increased expression of immune checkpoint genes and infiltration of immune cells, suggesting that immunotherapy was more likely to benefit the low-CIN score group. Additionally, drug sensitivity analysis indicated the high-CIN score group has lower sensitivity to several commonly used chemotherapeutic, endocrine, and targeted agents than the low-CIN score group. The novel gene signature, CIN score, identified in our research, offers a novel tool to predict the prognosis, TIME, and drug responsiveness in breast cancer, thus providing insights into immunotherapy decision-making and contributing to the precision treatment in breast cancer.
- 1 May 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (3) , 101924
Open AccessLeveraging a chromosomal instability-based signature to predict the prognosis and immune landscape of breast cancer
Chromosomal instability (CIN) significantly impacts the tumor progression and tumor immune microenvironment (TIME). However, few researchers have focused on CIN variables in predicting prognosis and the immune landscape of breast cancer. Through unsupervised consensus clustering, the TCGA-BRCA cohort was categorized into two clusters based on the CIN25 gene signature. After identifying the two clusters’ differentially expressed genes, we sequentially performed univariate Cox, LASSO, and multivariate Cox regression analyses to construct a 13-gene signature, termed “CIN score”. Then, the breast cancer patients were divided into low- and high-CIN score groups. The differences in survival outcome, clinicopathological parameters, TIME, and drug sensitivity between the two groups were further investigated. The high-CIN score group had unfavorable clinicopathological features and overall survival. TIME analysis indicated that the low-CIN score group had increased expression of immune checkpoint genes and infiltration of immune cells, suggesting that immunotherapy was more likely to benefit the low-CIN score group. Additionally, drug sensitivity analysis indicated the high-CIN score group has lower sensitivity to several commonly used chemotherapeutic, endocrine, and targeted agents than the low-CIN score group. The novel gene signature, CIN score, identified in our research, offers a novel tool to predict the prognosis, TIME, and drug responsiveness in breast cancer, thus providing insights into immunotherapy decision-making and contributing to the precision treatment in breast cancer.
- Open Access
- 28 March 2026
- Published by Elsevier in Asia-Pacific Journal of Oncology Nursing
- Vol. 13
Development of a nursing-sensitive quality evaluation indicator system for perioperative care in breast reconstruction surgery: A Delphi study
- 28 March 2026
- Published by Elsevier in Asia-Pacific Journal of Oncology Nursing
- Vol. 13
Open AccessDevelopment of a nursing-sensitive quality evaluation indicator system for perioperative care in breast reconstruction surgery: A Delphi study
- Open Access
- 17 September 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2557510
Genetic variations in CYP2A6 predict efficacy of neoadjuvant letrozole concurrent with chemotherapy in locally advanced hormone receptor-positive breast cancer
We conducted a retrospective exploratory analysis of prospective cohort to investigate the impact of CYP2A6 metabolizer status on predicting the efficacy and prognosis of neoadjuvant chemotherapy combined with letrozole. Three allelic variants that related to the abolished or reduced activity of CYP2A6 enzyme and 7 other single nucleotide polymorphisms (SNPs) in the CYP2A6 locus were examined from whole blood samples before neoadjuvant treatment, and patients were classified into 3 metabolizer status subgroups ('normal', 'intermediate' and 'slow' metabolizers) according to CYP2A6 genotypes. Our study included 56 patients received neoadjuvant chemotherapy combined with letrozole. The pCR rate in the CYP2A6 intermediate/slow metabolizers (29.2%) was higher than that in the normal metabolizers (12.5%; p = 0.046). Survival analysis suggested CYP2A6 intermediate/slow metabolizers may have a slightly lower risk of DFS events compared to normal metabolizers. These findings suggested that CYP2A6 metabolizer status might play a crucial role in predicting the efficacy and prognosis of adding letrozole to neoadjuvant chemotherapy. The CPY2A6 gene polymorphism may be a novel potential predictive and prognostic biomarker for postmenopausal hormone receptor-positive breast cancer patients receiving neoadjuvant chemotherapy combined with letrozole. Our findings have clinical implications for guiding precision endocrine therapy in hormone receptor-positive breast cancer patients.
- 17 September 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2557510
Open AccessGenetic variations in CYP2A6 predict efficacy of neoadjuvant letrozole concurrent with chemotherapy in locally advanced hormone receptor-positive breast cancer
We conducted a retrospective exploratory analysis of prospective cohort to investigate the impact of CYP2A6 metabolizer status on predicting the efficacy and prognosis of neoadjuvant chemotherapy combined with letrozole. Three allelic variants that related to the abolished or reduced activity of CYP2A6 enzyme and 7 other single nucleotide polymorphisms (SNPs) in the CYP2A6 locus were examined from whole blood samples before neoadjuvant treatment, and patients were classified into 3 metabolizer status subgroups ('normal', 'intermediate' and 'slow' metabolizers) according to CYP2A6 genotypes. Our study included 56 patients received neoadjuvant chemotherapy combined with letrozole. The pCR rate in the CYP2A6 intermediate/slow metabolizers (29.2%) was higher than that in the normal metabolizers (12.5%; p = 0.046). Survival analysis suggested CYP2A6 intermediate/slow metabolizers may have a slightly lower risk of DFS events compared to normal metabolizers. These findings suggested that CYP2A6 metabolizer status might play a crucial role in predicting the efficacy and prognosis of adding letrozole to neoadjuvant chemotherapy. The CPY2A6 gene polymorphism may be a novel potential predictive and prognostic biomarker for postmenopausal hormone receptor-positive breast cancer patients receiving neoadjuvant chemotherapy combined with letrozole. Our findings have clinical implications for guiding precision endocrine therapy in hormone receptor-positive breast cancer patients.
- Open Access
- 10 September 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (39) , 3713-3728
EMC2 promotes triple negative breast cancer growth by protecting FDFT1 from endoplasmic reticulum associated degradation to impair ferroptosis susceptibility
Cholesterol biosynthesis is more activated in triple negative breast cancer (TNBC) than in other subtype breast cancer and plays essential role in facilitating TNBC. However, the regulatory network and how cholesterol biosynthesis contribute to TNBC development and progression are not well elucidated. Here, we found that reticulum membrane protein complex 2 (EMC2) is highly expressed in TNBC and predicts short survival of patients. In vitro and in vivo experiments displayed that EMC2 could promote TNBC growth. We also displayed that EMC2 could increase intracellular cholesterol biosynthesis by regulating Farnesyltransferase 1 (FDFT1) expression. Mechanistically, we validated that EMC2 interacted with heat shock protein 90(HSP90) to sustain FDFT1 protein quality and correctly located in the ER membrane through protecting it from endoplasmic reticulum associated degradation (ERAD). Furthermore, EMC2 decreased TNBC cell ferroptosis susceptibility through elevating intracellular cholesterol contents. Collectively, our findings shed a new insight that EMC2 is critical for boosting cholesterol biosynthesis and ferroptosis resistance. Targeting EMC2 could be a promising novel therapeutic target for TNBC treatment.
- 10 September 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (39) , 3713-3728
Open AccessEMC2 promotes triple negative breast cancer growth by protecting FDFT1 from endoplasmic reticulum associated degradation to impair ferroptosis susceptibility
Cholesterol biosynthesis is more activated in triple negative breast cancer (TNBC) than in other subtype breast cancer and plays essential role in facilitating TNBC. However, the regulatory network and how cholesterol biosynthesis contribute to TNBC development and progression are not well elucidated. Here, we found that reticulum membrane protein complex 2 (EMC2) is highly expressed in TNBC and predicts short survival of patients. In vitro and in vivo experiments displayed that EMC2 could promote TNBC growth. We also displayed that EMC2 could increase intracellular cholesterol biosynthesis by regulating Farnesyltransferase 1 (FDFT1) expression. Mechanistically, we validated that EMC2 interacted with heat shock protein 90(HSP90) to sustain FDFT1 protein quality and correctly located in the ER membrane through protecting it from endoplasmic reticulum associated degradation (ERAD). Furthermore, EMC2 decreased TNBC cell ferroptosis susceptibility through elevating intracellular cholesterol contents. Collectively, our findings shed a new insight that EMC2 is critical for boosting cholesterol biosynthesis and ferroptosis resistance. Targeting EMC2 could be a promising novel therapeutic target for TNBC treatment.
- Open Access
- 1 September 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Metronomic chemotherapy of paclitaxel plus cisplatin in patients with metastatic breast cancer: a target trial emulation study
Background: As metastasis drives the majority of breast cancer-related deaths, improving outcomes for metastatic breast cancer (MBC) remains a crucial challenge. Observational studies using target trial emulation are increasingly applied to estimate treatment effects, providing insights when randomized trials are not viable. Objectives: To estimate the effect of progression-free survival (PFS) of metronomic chemotherapy of weekly paclitaxel plus cisplatin (DP) compared with treatment of the physician’s choice (TPC) for MBC. Design: This analysis was designed as a retrospective cohort study according to STROBE criteria. Methods: This retrospective cohort study compared metronomic chemotherapy of weekly DP versus TPC in MBC. The DP regimen included paclitaxel (80 mg/m 2 ) on days 1, 8, 15, 22 and cisplatin (25 mg/m 2 ) on days 1, 8, 15 in a 28-day cycle. Women aged ⩾18 years with MBC treated with at least one prior therapy between April 2014 and January 2023 at Renji Hospital were included. Propensity score matching (1:3) adjusted for confounding. The matched cohort subsequently underwent emulation of a randomized target trial, including cloning, censoring and weighting. The primary endpoint was PFS. Results: Among 313 matched patients (83 on DP, 230 on TPC), DP showed a median PFS of 13.5 months (95% CI 10.3–16.6) versus 7.9 months (95% CI: 6.7–9.1) for TPC (hazard ratio (HR) 0.77, 95% CI 0.60–0.99). Target trial emulation further improved PFS in the DP arm to 14.1 months (95% CI: 13.3–16.6) versus 8.3 months (95% CI: 8.0–8.6) for TPC (HR 0.59, 95% CI: 0.54–0.64). Subgroup analysis and sensitivity analyses confirmed result robustness. Conclusion: This study demonstrates that weekly metronomic DP chemotherapy reduces disease progression in MBC patients, particularly in first-line settings. These findings support its potential as a treatment option and warrant further study for broader application.
- 1 September 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Open AccessMetronomic chemotherapy of paclitaxel plus cisplatin in patients with metastatic breast cancer: a target trial emulation study
Background: As metastasis drives the majority of breast cancer-related deaths, improving outcomes for metastatic breast cancer (MBC) remains a crucial challenge. Observational studies using target trial emulation are increasingly applied to estimate treatment effects, providing insights when randomized trials are not viable. Objectives: To estimate the effect of progression-free survival (PFS) of metronomic chemotherapy of weekly paclitaxel plus cisplatin (DP) compared with treatment of the physician’s choice (TPC) for MBC. Design: This analysis was designed as a retrospective cohort study according to STROBE criteria. Methods: This retrospective cohort study compared metronomic chemotherapy of weekly DP versus TPC in MBC. The DP regimen included paclitaxel (80 mg/m 2 ) on days 1, 8, 15, 22 and cisplatin (25 mg/m 2 ) on days 1, 8, 15 in a 28-day cycle. Women aged ⩾18 years with MBC treated with at least one prior therapy between April 2014 and January 2023 at Renji Hospital were included. Propensity score matching (1:3) adjusted for confounding. The matched cohort subsequently underwent emulation of a randomized target trial, including cloning, censoring and weighting. The primary endpoint was PFS. Results: Among 313 matched patients (83 on DP, 230 on TPC), DP showed a median PFS of 13.5 months (95% CI 10.3–16.6) versus 7.9 months (95% CI: 6.7–9.1) for TPC (hazard ratio (HR) 0.77, 95% CI 0.60–0.99). Target trial emulation further improved PFS in the DP arm to 14.1 months (95% CI: 13.3–16.6) versus 8.3 months (95% CI: 8.0–8.6) for TPC (HR 0.59, 95% CI: 0.54–0.64). Subgroup analysis and sensitivity analyses confirmed result robustness. Conclusion: This study demonstrates that weekly metronomic DP chemotherapy reduces disease progression in MBC patients, particularly in first-line settings. These findings support its potential as a treatment option and warrant further study for broader application.
- Open Access
- 13 June 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (6) , 350
Dynamic Evolution of Vascular Features Based on Magnetic Resonance Imaging to Predict Pathological Response, Patterns of Recurrence and Survival Outcomes in Breast Cancer Neoadjuvant Chemotherapy
Neoadjuvant chemotherapy (NAC), followed by surgery and adjuvant therapy, constitutes the prevailing therapeutic paradigm for patients with locally advanced breast cancer (LABC)
- 13 June 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (6) , 350
Open AccessDynamic Evolution of Vascular Features Based on Magnetic Resonance Imaging to Predict Pathological Response, Patterns of Recurrence and Survival Outcomes in Breast Cancer Neoadjuvant Chemotherapy
Neoadjuvant chemotherapy (NAC), followed by surgery and adjuvant therapy, constitutes the prevailing therapeutic paradigm for patients with locally advanced breast cancer (LABC)
- Open Access
- 7 February 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (2) , 93
Measurement of Intratumor Heterogeneity and Its Changing Pattern to Predict Response and Recurrence Risk After Neoadjuvant Chemotherapy in Breast Cancer
The heterogeneity of breast tumors might reflect biological complexity and provide prediction clues for the sensitivity of treatment. This study aimed to construct a model based on tumor heterogeneity in magnetic resonance imaging (MRI) for predicting the pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). This retrospective study involved 217 patients with biopsy-confirmed invasive breast cancer who underwent MR before and after NAC. Patients were randomly divided into the training cohort and the validation cohort at a 1:1 ratio. MR images were processed by algorithms to quantify the heterogeneity of tumors. Models incorporating heterogeneity and clinical characteristics were constructed to predict pCR. The patterns of heterogeneity variation during NAC were classified into four categories abbreviated as the heterogeneity high-keep group (H_keep group), heterogeneity low-keep group (L_keep group), heterogeneity rising group, and decrease group. The average heterogeneity in patients achieving pCR was significantly lower than in those who did not (p = 0.029). Lower heterogeneity was independently associated with pCR (OR, 0.401 [95%CI: 0.21, 0.76]; p = 0.007). The model combining heterogeneity and clinical characteristics demonstrated improved specificity (True Negative Rate 0.857 vs. 0.698) and accuracy (Accuracy 0.828 vs. 0.753) compared to the clinical model. Survival outcomes were best for the L_keep group and worst for the rising group (Log-rank p = 0.031). Patients with increased heterogeneity exhibited a higher risk of recurrence approaching two years post-surgery, particularly within the non-pCR population. The quantified heterogeneity of breast cancer in MRI offers a non-invasive method for predicting pCR to NAC and evaluating the implementation of precision medicine.
- 7 February 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (2) , 93
Open AccessMeasurement of Intratumor Heterogeneity and Its Changing Pattern to Predict Response and Recurrence Risk After Neoadjuvant Chemotherapy in Breast Cancer
The heterogeneity of breast tumors might reflect biological complexity and provide prediction clues for the sensitivity of treatment. This study aimed to construct a model based on tumor heterogeneity in magnetic resonance imaging (MRI) for predicting the pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). This retrospective study involved 217 patients with biopsy-confirmed invasive breast cancer who underwent MR before and after NAC. Patients were randomly divided into the training cohort and the validation cohort at a 1:1 ratio. MR images were processed by algorithms to quantify the heterogeneity of tumors. Models incorporating heterogeneity and clinical characteristics were constructed to predict pCR. The patterns of heterogeneity variation during NAC were classified into four categories abbreviated as the heterogeneity high-keep group (H_keep group), heterogeneity low-keep group (L_keep group), heterogeneity rising group, and decrease group. The average heterogeneity in patients achieving pCR was significantly lower than in those who did not (p = 0.029). Lower heterogeneity was independently associated with pCR (OR, 0.401 [95%CI: 0.21, 0.76]; p = 0.007). The model combining heterogeneity and clinical characteristics demonstrated improved specificity (True Negative Rate 0.857 vs. 0.698) and accuracy (Accuracy 0.828 vs. 0.753) compared to the clinical model. Survival outcomes were best for the L_keep group and worst for the rising group (Log-rank p = 0.031). Patients with increased heterogeneity exhibited a higher risk of recurrence approaching two years post-surgery, particularly within the non-pCR population. The quantified heterogeneity of breast cancer in MRI offers a non-invasive method for predicting pCR to NAC and evaluating the implementation of precision medicine.